newsfilter
← Latest News
Business Wire·

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

– Company Continues to Expect Nedosiran New Drug Application Submission in Fourth Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RN